<p>Delcath Systems, Inc.（纳斯达克代码：DCTH - 免费报告）- HC Wainwright 的股票研究分析师在 8 月 7 日星期四发布的研究报告中下调了对 Delcath Systems 2026 年第一季度每股收益的预期。HC Wainwright 分析师 S. Ramakanth 现在预计该公司本季度每股收益为 0.09 美元，低于之前的 0.13 美元的预期。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 31.00 美元。市场普遍预计 Delcath Systems 当前全年的每股收益为（0.79 美元）。HC Wainwright 还对 Delcath Systems 2026 年第二季度的每股收益预期为 0.06 美元，第三季度为 0.27 美元，第四季度为 0.27 美元，2027 财年的每股收益为 1.48 美元，2028 财年的每股收益为 2.02 美元，以及 2029 财年的每股收益为 2.55 美元。</p>
<p>Delcath Systems（纳斯达克代码：DCTH - 获取免费报告）于 8 月 6 日星期三发布了最新的财报。该公司报告本季度每股收益为 0.07 美元，超出分析师普遍预期的 0.02 美元，超出幅度为 0.05 美元。Delcath Systems 的净利润率为 3.18%，股本回报率为 8.63%。该公司本季度的收入为 2416 万美元，而分析师的预期为 2284 万美元。</p>
<p>获取 <strong>Delcath Systems</strong> 的提醒：</p>
<p>其他股票分析师最近也发布了关于该股票的研究报告。Stephens 在 6 月 23 日星期一重申了 “增持” 评级，并对 Delcath Systems 的股票设定了 25.00 美元的目标价。华尔街 Zen 在 8 月 2 日星期六将 Delcath Systems 的股票评级从 “持有” 上调至 “买入”。根据 MarketBeat 的数据，五位研究分析师对该股票给予了买入评级，Delcath Systems 的共识评级为 “买入”，平均目标价为 24.50 美元。</p>
<p><strong>查看我们关于 Delcath Systems 的最新报告</strong></p>
<h2>Delcath Systems 股票表现</h2>
<p>Delcath Systems 股票在周五的午盘交易中下跌 0.13 美元，报 10.06 美元。该股票交易量为 132,421 股，而其平均交易量为 573,181 股。该公司的 50 日移动平均线为 13.08 美元，200 日移动平均线为 13.64 美元。该公司的市值为 3.5042 亿美元，市盈率为 201.80，贝塔系数为 0.82。Delcath Systems 的 52 周低点为 7.17 美元，52 周高点为 18.23 美元。</p>
<h2>对 Delcath Systems 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近对 DCTH 的持仓进行了调整。Soleus Capital Management L.P. 在第四季度购买了 Delcath Systems 的新股份，价值 9,644,000 美元。Vivo Capital LLC 在第四季度将其在 Delcath Systems 的股份增加了 71.4%。Vivo Capital LLC 现在拥有 1,708,579 股该公司的股票，价值 20,571,000 美元，此前在该期间又购买了 711,574 股。Gilder Gagnon Howe &amp; Co. LLC 在第四季度购买了 Delcath Systems 的新股份，价值约 7,371,000 美元。Invesco Ltd. 在第一季度购买了 Delcath Systems 的新股份，价值约 5,084,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 Delcath Systems 的持股增加了 128.1%。Geode Capital Management LLC 现在拥有 703,171 股该公司的股票，价值 9,565,000 美元，此前在上个季度又购买了 394,902 股。对冲基金和其他机构投资者持有该公司 61.12% 的股份。</p>
<h2>Delcath Systems 公司简介</h2>
<p>（获取免费报告）</p>
<p>Delcath Systems, Inc. 是一家介入性肿瘤学公司，专注于在美国和欧洲治疗原发性和转移性肝癌。该公司的主要产品候选是 HEPZATO KIT，一种用于注射的美法仑/肝脏给药系统，用于向肝脏施用高剂量化疗，同时控制全身暴露和相关副作用。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Delcath Systems</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>复利是如何计算的？</li>
<li>DraftKings 发布创纪录的季度业绩，瞄准盈利能力</li>
<li>10 只最佳航空公司股票</li>
<li>亚马逊在 IonQ 中获得股权投资——是否有上涨潜力？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RENUSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RENUSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Delcath Systems 吗？</h2>
<p>在您考虑 Delcath Systems 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Delcath Systems 并不在名单上。</p>
<p>虽然 Delcath Systems 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DCTH

<p>HC Wainwright 的股票研究分析师将 Delcath Systems 2026 年第一季度的每股收益（EPS）预期从 0.13 美元下调至 0.09 美元。该公司维持 “买入” 评级，目标价为 31.00 美元。Delcath 最近的财报显示每股收益为 0.07 美元，超出预期。分析师预计 2026 年第二季度的未来收益为 0.06 美元，2026 年第三季度和第四季度为 0.27 美元，2027 财年的收益为 1.48 美元。该股票目前交易价格为 10.06 美元，市值为 3.5042 亿美元，市场共识评级为 “买入”</p>

<p>Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Delcath Systems in a research note issued on Thursday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.09 for the quarter, down from their prior estimate of $0.13. HC Wainwright currently has a &#34;Buy&#34; rating and a $31.00 price objective on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems' Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.27 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $2.02 EPS and FY2029 earnings at $2.55 EPS.</p>
<div class="lb-trans"><p>Delcath Systems, Inc.（纳斯达克代码：DCTH - 免费报告）- HC Wainwright 的股票研究分析师在 8 月 7 日星期四发布的研究报告中下调了对 Delcath Systems 2026 年第一季度每股收益的预期。HC Wainwright 分析师 S. Ramakanth 现在预计该公司本季度每股收益为 0.09 美元，低于之前的 0.13 美元的预期。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 31.00 美元。市场普遍预计 Delcath Systems 当前全年的每股收益为（0.79 美元）。HC Wainwright 还对 Delcath Systems 2026 年第二季度的每股收益预期为 0.06 美元，第三季度为 0.27 美元，第四季度为 0.27 美元，2027 财年的每股收益为 1.48 美元，2028 财年的每股收益为 2.02 美元，以及 2029 财年的每股收益为 2.55 美元。</p>
</div><p>Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 8.63%. The firm had revenue of $24.16 million for the quarter, compared to analysts' expectations of $22.84 million.</p>
<div class="lb-trans"><p>Delcath Systems（纳斯达克代码：DCTH - 获取免费报告）于 8 月 6 日星期三发布了最新的财报。该公司报告本季度每股收益为 0.07 美元，超出分析师普遍预期的 0.02 美元，超出幅度为 0.05 美元。Delcath Systems 的净利润率为 3.18%，股本回报率为 8.63%。该公司本季度的收入为 2416 万美元，而分析师的预期为 2284 万美元。</p>
</div><p>Get <strong>Delcath Systems</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Delcath Systems</strong> 的提醒：</p>
</div><p>Other equities analysts have also recently issued research reports about the stock. Stephens reissued an &#34;overweight&#34; rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. Wall Street Zen upgraded shares of Delcath Systems from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 2nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Delcath Systems has a consensus rating of &#34;Buy&#34; and an average price target of $24.50.</p>
<div class="lb-trans"><p>其他股票分析师最近也发布了关于该股票的研究报告。Stephens 在 6 月 23 日星期一重申了 “增持” 评级，并对 Delcath Systems 的股票设定了 25.00 美元的目标价。华尔街 Zen 在 8 月 2 日星期六将 Delcath Systems 的股票评级从 “持有” 上调至 “买入”。根据 MarketBeat 的数据，五位研究分析师对该股票给予了买入评级，Delcath Systems 的共识评级为 “买入”，平均目标价为 24.50 美元。</p>
</div><p><strong>View Our Latest Report on Delcath Systems</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Delcath Systems 的最新报告</strong></p>
</div><h2>Delcath Systems Stock Performance</h2>
<div class="lb-trans"><h2>Delcath Systems 股票表现</h2>
</div><p>Delcath Systems stock traded down $0.13 during midday trading on Friday, reaching $10.06. 132,421 shares of the stock were exchanged, compared to its average volume of 573,181. The company's fifty day moving average is $13.08 and its 200-day moving average is $13.64. The firm has a market cap of $350.42 million, a PE ratio of 201.80 and a beta of 0.82. Delcath Systems has a 52 week low of $7.17 and a 52 week high of $18.23.</p>
<div class="lb-trans"><p>Delcath Systems 股票在周五的午盘交易中下跌 0.13 美元，报 10.06 美元。该股票交易量为 132,421 股，而其平均交易量为 573,181 股。该公司的 50 日移动平均线为 13.08 美元，200 日移动平均线为 13.64 美元。该公司的市值为 3.5042 亿美元，市盈率为 201.80，贝塔系数为 0.82。Delcath Systems 的 52 周低点为 7.17 美元，52 周高点为 18.23 美元。</p>
</div><h2>Hedge Funds Weigh In On Delcath Systems</h2>
<div class="lb-trans"><h2>对 Delcath Systems 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in DCTH. Soleus Capital Management L.P. bought a new stake in Delcath Systems in the 4th quarter valued at $9,644,000. Vivo Capital LLC boosted its stake in shares of Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after purchasing an additional 711,574 shares during the period. Gilder Gagnon Howe &amp; Co. LLC purchased a new position in shares of Delcath Systems during the 4th quarter worth about $7,371,000. Invesco Ltd. bought a new stake in Delcath Systems during the 1st quarter valued at about $5,084,000. Finally, Geode Capital Management LLC lifted its holdings in Delcath Systems by 128.1% during the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company's stock valued at $9,565,000 after buying an additional 394,902 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 DCTH 的持仓进行了调整。Soleus Capital Management L.P. 在第四季度购买了 Delcath Systems 的新股份，价值 9,644,000 美元。Vivo Capital LLC 在第四季度将其在 Delcath Systems 的股份增加了 71.4%。Vivo Capital LLC 现在拥有 1,708,579 股该公司的股票，价值 20,571,000 美元，此前在该期间又购买了 711,574 股。Gilder Gagnon Howe &amp; Co. LLC 在第四季度购买了 Delcath Systems 的新股份，价值约 7,371,000 美元。Invesco Ltd. 在第一季度购买了 Delcath Systems 的新股份，价值约 5,084,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 Delcath Systems 的持股增加了 128.1%。Geode Capital Management LLC 现在拥有 703,171 股该公司的股票，价值 9,565,000 美元，此前在上个季度又购买了 394,902 股。对冲基金和其他机构投资者持有该公司 61.12% 的股份。</p>
</div><h2>Delcath Systems Company Profile</h2>
<div class="lb-trans"><h2>Delcath Systems 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.</p>
<div class="lb-trans"><p>Delcath Systems, Inc. 是一家介入性肿瘤学公司，专注于在美国和欧洲治疗原发性和转移性肝癌。该公司的主要产品候选是 HEPZATO KIT，一种用于注射的美法仑/肝脏给药系统，用于向肝脏施用高剂量化疗，同时控制全身暴露和相关副作用。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Delcath Systems</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>How is Compound Interest Calculated?</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Delcath Systems</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>复利是如何计算的？</li>
<li>DraftKings 发布创纪录的季度业绩，瞄准盈利能力</li>
<li>10 只最佳航空公司股票</li>
<li>亚马逊在 IonQ 中获得股权投资——是否有上涨潜力？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RENUSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DCTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Delcath Systems Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Delcath Systems 吗？</h2>
</div><p>Before you consider Delcath Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Delcath Systems 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Delcath Systems 并不在名单上。</p>
</div><p>While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Delcath Systems 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

经纪商对 Delcath Systems 第一季度收益的预测